The applicability of biomonitoring data for perfluorooctanesulfonate to the environmental public health continuum
- PMID: 17107867
- PMCID: PMC1665413
- DOI: 10.1289/ehp.9060
The applicability of biomonitoring data for perfluorooctanesulfonate to the environmental public health continuum
Abstract
Perfluorooctanesulfonate and its salts (PFOS) are derived from perfluorooctanesulfonyl fluoride, the basic chemical building block for many sulfonyl-based fluorochemicals used as surfactants and for their repellent properties. PFOS is highly persistent in the environment and has a long serum elimination half-life in both animals and humans. PFOS has been detected globally in the environment and in blood serum in various populations throughout the world, with the majority of human sampling done in the United States and Japan. The mechanisms and pathways leading to the presence of PFOS in human blood are not well characterized but likely involve both direct exposures to PFOS or chemicals and materials that can degrade to PFOS, either in the environment or from industrial and commercial uses. In 2000 the 3M Company, a major manufacturer, announced a phaseout of PFOS-related materials. Animal studies indicate that PFOS is well absorbed orally and distributes mainly in blood serum and the liver. Several repeat-dose toxicology studies in animals consistently demonstrated that the liver is the primary target organ. In addition there is a steep dose response for mortality in sexually mature rats and primates as well as in neonatal rats and mice exposed in utero. Several biomonitoring research needs that have been identified on PFOS include additional data from general populations pertaining to other matrices besides blood; matched serum and urine samples from humans and research animals; and comparison of whole blood, serum, and plasma concentrations from the same individuals.
Similar articles
-
Decline in perfluorooctanesulfonate and other polyfluoroalkyl chemicals in American Red Cross adult blood donors, 2000-2006.Environ Sci Technol. 2008 Jul 1;42(13):4989-95. doi: 10.1021/es800071x. Environ Sci Technol. 2008. PMID: 18678038
-
Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys.Reprod Toxicol. 2012 Jul;33(4):428-440. doi: 10.1016/j.reprotox.2011.07.002. Epub 2011 Aug 11. Reprod Toxicol. 2012. PMID: 21889587
-
Toxicokinetics of perfluorooctane sulfonate in rabbits under environmentally realistic exposure conditions and comparative assessment between mammals and birds.Toxicol Lett. 2016 Jan 22;241:200-6. doi: 10.1016/j.toxlet.2015.11.002. Epub 2015 Nov 10. Toxicol Lett. 2016. PMID: 26562771
-
PFOS or PreFOS? Are perfluorooctane sulfonate precursors (PreFOS) important determinants of human and environmental perfluorooctane sulfonate (PFOS) exposure?J Environ Monit. 2010 Nov;12(11):1979-2004. doi: 10.1039/c0em00295j. Epub 2010 Oct 13. J Environ Monit. 2010. PMID: 20944836 Review.
-
Distributions of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) in Japan and their toxicities.Environ Sci. 2005;12(6):293-313. Environ Sci. 2005. PMID: 16609670 Review.
Cited by
-
The use of biomonitoring data in exposure and human health risk assessments.Environ Health Perspect. 2006 Nov;114(11):1755-62. doi: 10.1289/ehp.9056. Environ Health Perspect. 2006. PMID: 17107864 Free PMC article.
-
Mechanistic Insights into PFOS-Mediated Sertoli Cell Injury.Trends Mol Med. 2018 Sep;24(9):781-793. doi: 10.1016/j.molmed.2018.07.001. Epub 2018 Jul 25. Trends Mol Med. 2018. PMID: 30056046 Free PMC article. Review.
-
Translating biomonitoring data into risk management and policy implementation options for a European Network on Human Biomonitoring.Environ Health. 2008 Jun 5;7 Suppl 1(Suppl 1):S2. doi: 10.1186/1476-069X-7-S1-S2. Environ Health. 2008. PMID: 18541068 Free PMC article.
-
Umbilical cord serum concentrations of perfluorooctane sulfonate, perfluorooctanoic acid, and the body mass index changes from birth to 5 1/2 years of age.Sci Rep. 2021 Oct 5;11(1):19789. doi: 10.1038/s41598-021-99174-3. Sci Rep. 2021. PMID: 34611219 Free PMC article.
-
Assessment of a mouse xenograft model of primary colorectal cancer with special reference to perfluorooctane sulfonate.PeerJ. 2018 Nov 2;6:e5602. doi: 10.7717/peerj.5602. eCollection 2018. PeerJ. 2018. PMID: 30405966 Free PMC article.
References
-
- 3M Company 2000. Phase-out Plan for POSF-Based Products. Letter from William Weppner (3M Company) to Charles Auer (U.S. EPA). 7 July 2000. U.S. EPA docket AR-226-0600. Washington, DC:U.S. Environmental Protection Agency.
-
- 3M Company 2001. Production of PFOS Derivatives. E-mail letter from Mike Santoro (3M Company) to Charles Auer (U.S. EPA). 2 March 2001. U.S. EPA docket AR-226-0997. Washington, DC:U.S. Environmental Protection Agency.
-
- 3M Company 2002. 104-Week Dietary Chronic Toxicity and Carcinogenicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Rats. Final Report. 3M Company, St. Paul, MN. 2 January 2002. U.S. EPA docket AR-226-0956. Washington, DC:U.S. Environmental Protection Agency.
-
- 3M Company 2003. Environmental and Health Assessment of Perfluorooctanesulfonate and Its Salts. 3M Company, 20 August 2003. U.S. EPA docket AR-226-1486. Washington, DC:U.S. Environmental Protection Agency.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources